Georgetown University

Encouraging results from a small Phase 2 human trial testing the effects of a cancer drug in treating Alzheimer’s disease suggest the drug is safe, well-tolerated and alters biomarkers associated with Alzheimer’s. A larger study is currently planned.

Medical researchers have developed a blood test which predicts with 90 percent accuracy if an individual will develop Alzheimer's disease or mild cognitive impairment (MCI) within three years.